LAB - Latest News
Standard BioTools Inc. (LAB), operates in Healthcare / Medical - Equipment & Services, trades on NASDAQ.
Market capitalization stands near $278.9M. Beta to the broader market is 1.40.
The article list below shows the most recent LAB headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent LAB Headlines
Standard BioTools Reports Second Quarter 2026 Financial Results
globenewswire.com - Aug 5, 2026
BOSTON, Mass. , Aug.
Standard BioTools Reports Second Quarter 2026 Financial Results
globenewswire.com - Aug 5, 2026
BOSTON, Mass. , Aug.
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
globenewswire.com - Jul 28, 2026
Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team a
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
globenewswire.com - Jul 22, 2026
BOSTON, Mass. , July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc.
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?
gurufocus.com - Jul 21, 2026
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?
How News Affects LAB Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track LAB's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked LAB news questions
- What is the latest LAB news headline?
- The most recent LAB headline (Aug 5, 2026) is "Standard BioTools Reports Second Quarter 2026 Financial Results". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the LAB news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What LAB news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual LAB options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.